Medpace Faces Class Action Lawsuit Impacting Stock Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MEDP?
Source: Globenewswire
- Class Action Initiated: Medpace Holdings, Inc. is facing a class action lawsuit due to misleading positive statements made between April 22, 2025, and February 9, 2026, under case number 1:26-cv-00346, highlighting serious deficiencies in the company's financial transparency.
- Stock Price Plummets: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the expected 1.15, Medpace's stock price dropped from $530.35 to $446.05, a decline exceeding 15.9%, reflecting market disappointment in the company's outlook.
- Investor Loss Compensation: Levi & Korsinsky is committed to ensuring full compensation for investors who suffered losses due to corporate misrepresentations, urging shareholders to step forward before the June 8, 2026 deadline to seek justice as lead plaintiffs.
- Legal Team Expertise: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has a team of over 70 employees, consistently ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing their extensive experience in complex securities litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 496.000
Low
462.00
Averages
569.17
High
660.00
Current: 496.000
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace for investors who purchased shares between April 22, 2025, and February 9, 2026, indicating significant legal risks that could impact the company's stock performance.
- Allegations of False Statements: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which resulted in investor losses when the truth emerged, highlighting serious issues with the company's governance and transparency.
- Investor Rights Protection: Investors must apply by June 5, 2026, to be appointed as lead plaintiffs, indicating the urgency of the legal process, which could affect Medpace's reputation and future financing capabilities.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities and commercial litigation, demonstrating the firm's capability to handle complex securities cases, which could significantly influence the legal outcomes for Medpace.
See More
Faruqi & Faruqi Investigates Medpace Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Medpace Holdings, Inc., particularly for investors who purchased securities between April 22, 2025, and February 9, 2026, urging them to apply for lead plaintiff status in the federal securities class action by the June 8, 2026 deadline.
- False Statement Allegations: The complaint alleges that Medpace provided overly positive statements while concealing significant adverse facts regarding its backlog cancellation rate, leading to unrealistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Stock Price Volatility: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the guidance of 1.15, Medpace's stock price plummeted from $530.35 to $446.05, a decline of over 15.9%, indicating market concerns about the company's financial health.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Medpace's conduct, including whistleblowers and former employees, to contact the firm to provide legal support and share information for affected investors.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Medpace Holdings, Inc. is facing a class action lawsuit due to misleading positive statements made between April 22, 2025, and February 9, 2026, under case number 1:26-cv-00346, highlighting serious deficiencies in the company's financial transparency.
- Stock Price Plummets: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the expected 1.15, Medpace's stock price dropped from $530.35 to $446.05, a decline exceeding 15.9%, reflecting market disappointment in the company's outlook.
- Investor Loss Compensation: Levi & Korsinsky is committed to ensuring full compensation for investors who suffered losses due to corporate misrepresentations, urging shareholders to step forward before the June 8, 2026 deadline to seek justice as lead plaintiffs.
- Legal Team Expertise: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has a team of over 70 employees, consistently ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing their extensive experience in complex securities litigation.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Medpace Holdings, Inc. to recover damages for investors who purchased securities between April 22, 2025, and February 9, 2026, highlighting significant investor concerns regarding financial transparency.
- False Statements Allegations: The complaint alleges that Medpace misrepresented its expected book-to-bill ratio as approximately 1.15 during earnings calls, despite having contrary internal information, which misled investors about the company's future prospects and could negatively impact stock prices.
- Investor Rights Protection: Affected investors have until June 5, 2026, to apply to be lead plaintiffs, demonstrating the legal team's commitment to safeguarding investor rights and emphasizing the importance of corporate governance and transparency.
- No-Cost Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency-based legal services, charging fees only upon successful recovery, which reduces legal risks for investors and encourages more victims to participate in the lawsuit.
See More
Medpace Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Medpace Holdings, Inc. is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements regarding its book-to-bill ratio for Q4 2025, failing to disclose the adverse impact of cancellations, which may have led to significant investor losses.
- Investor Rights: Investors who purchased Medpace shares between April 22, 2025, and February 9, 2026, and experienced substantial losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, highlighting the firm's commitment to shareholder interests.
- Legal Proceedings: Investors must apply to be appointed lead plaintiff by June 5, 2026, indicating the urgency of the case and its potential impact on Medpace's market reputation and stock price.
- Law Firm Background: Holzer & Holzer, established in 2000, focuses on providing legal support to shareholders and investors, having recovered hundreds of millions for victims of fraud, demonstrating its expertise and success in securities litigation.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses once the truth was revealed, indicating significant misrepresentation in the company's public statements.
- Opportunity for Loss Recovery: Affected shareholders are encouraged to join the lawsuit to seek compensation, with the Schall Law Firm specializing in securities class actions and offering free consultations to help investors understand their rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their rights to claim damages.
See More
Medpace Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace for investors who purchased shares between April 22, 2025, and February 9, 2026, indicating significant legal risks that could impact the company's stock performance.
- Allegations of False Statements: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which resulted in investor losses when the truth emerged, highlighting serious issues with the company's governance and transparency.
- Investor Rights Protection: Investors must apply by June 5, 2026, to be appointed as lead plaintiffs, indicating the urgency of the legal process, which could affect Medpace's reputation and future financing capabilities.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities and commercial litigation, demonstrating the firm's capability to handle complex securities cases, which could significantly influence the legal outcomes for Medpace.
See More
Faruqi & Faruqi Investigates Medpace Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Medpace Holdings, Inc., particularly for investors who purchased securities between April 22, 2025, and February 9, 2026, urging them to apply for lead plaintiff status in the federal securities class action by the June 8, 2026 deadline.
- False Statement Allegations: The complaint alleges that Medpace provided overly positive statements while concealing significant adverse facts regarding its backlog cancellation rate, leading to unrealistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Stock Price Volatility: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the guidance of 1.15, Medpace's stock price plummeted from $530.35 to $446.05, a decline of over 15.9%, indicating market concerns about the company's financial health.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Medpace's conduct, including whistleblowers and former employees, to contact the firm to provide legal support and share information for affected investors.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Medpace Holdings, Inc. is facing a class action lawsuit due to misleading positive statements made between April 22, 2025, and February 9, 2026, under case number 1:26-cv-00346, highlighting serious deficiencies in the company's financial transparency.
- Stock Price Plummets: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the expected 1.15, Medpace's stock price dropped from $530.35 to $446.05, a decline exceeding 15.9%, reflecting market disappointment in the company's outlook.
- Investor Loss Compensation: Levi & Korsinsky is committed to ensuring full compensation for investors who suffered losses due to corporate misrepresentations, urging shareholders to step forward before the June 8, 2026 deadline to seek justice as lead plaintiffs.
- Legal Team Expertise: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has a team of over 70 employees, consistently ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing their extensive experience in complex securities litigation.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Medpace Holdings, Inc. to recover damages for investors who purchased securities between April 22, 2025, and February 9, 2026, highlighting significant investor concerns regarding financial transparency.
- False Statements Allegations: The complaint alleges that Medpace misrepresented its expected book-to-bill ratio as approximately 1.15 during earnings calls, despite having contrary internal information, which misled investors about the company's future prospects and could negatively impact stock prices.
- Investor Rights Protection: Affected investors have until June 5, 2026, to apply to be lead plaintiffs, demonstrating the legal team's commitment to safeguarding investor rights and emphasizing the importance of corporate governance and transparency.
- No-Cost Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency-based legal services, charging fees only upon successful recovery, which reduces legal risks for investors and encourages more victims to participate in the lawsuit.
See More
Medpace Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Medpace Holdings, Inc. is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements regarding its book-to-bill ratio for Q4 2025, failing to disclose the adverse impact of cancellations, which may have led to significant investor losses.
- Investor Rights: Investors who purchased Medpace shares between April 22, 2025, and February 9, 2026, and experienced substantial losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, highlighting the firm's commitment to shareholder interests.
- Legal Proceedings: Investors must apply to be appointed lead plaintiff by June 5, 2026, indicating the urgency of the case and its potential impact on Medpace's market reputation and stock price.
- Law Firm Background: Holzer & Holzer, established in 2000, focuses on providing legal support to shareholders and investors, having recovered hundreds of millions for victims of fraud, demonstrating its expertise and success in securities litigation.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses once the truth was revealed, indicating significant misrepresentation in the company's public statements.
- Opportunity for Loss Recovery: Affected shareholders are encouraged to join the lawsuit to seek compensation, with the Schall Law Firm specializing in securities class actions and offering free consultations to help investors understand their rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their rights to claim damages.
See More
